199 related articles for article (PubMed ID: 18491983)
1. Single annual injectable treatment for postmenopausal osteoporosis.
Chapurlat RD
Expert Opin Drug Deliv; 2008 May; 5(5):583-91. PubMed ID: 18491983
[TBL] [Abstract][Full Text] [Related]
2. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
3. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
[TBL] [Abstract][Full Text] [Related]
4. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
6. Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture.
Chapurlat RD
Ther Clin Risk Manag; 2009 Apr; 5(2):169-75. PubMed ID: 19536314
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
8. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
9. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
Hwang JS; Chin LS; Chen JF; Yang TS; Chen PQ; Tsai KS; Leung PC
J Bone Miner Metab; 2011 May; 29(3):328-33. PubMed ID: 20922438
[TBL] [Abstract][Full Text] [Related]
10. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Geusens PP; Lems WF
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1445-8. PubMed ID: 17633971
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
12. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
Cauley JA; Black D; Boonen S; Cummings SR; Mesenbrink P; Palermo L; Man Z; Hadji P; Reid IR;
J Bone Miner Res; 2011 May; 26(5):984-92. PubMed ID: 21542001
[TBL] [Abstract][Full Text] [Related]
13. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis.
Fardellone P; Cortet B; Legrand E; Bresse X; Bisot-Locard S; Vigneron AM; Beresniak A
Joint Bone Spine; 2010 Jan; 77(1):53-7. PubMed ID: 20034831
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C
Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW; Colón-Emeric CS; Magaziner JS; Adachi JD; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Lavecchia C; Zhang J; Mesenbrink P; Hodgson PK; Abrams K; Orloff JJ; Horowitz Z; Eriksen EF; Boonen S;
N Engl J Med; 2007 Nov; 357(18):1799-809. PubMed ID: 17878149
[TBL] [Abstract][Full Text] [Related]
19. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
[TBL] [Abstract][Full Text] [Related]
20. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
Lambrinoudaki I; Vlachou S; Galapi F; Papadimitriou D; Papadias K
Clin Interv Aging; 2008; 3(3):445-51. PubMed ID: 18982915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
